About
Deep Eutectic Ionic Liquids for Therapeutics
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
9
As Collaborator
0
Total Enrollment
430
By Phase
PHASE2: 3PHASE1/PHASE2: 1EARLY_PHASE1: 1PHASE1: 2NA: 1
By Status
COMPLETED: 6NOT_YET_RECRUITING: 1RECRUITING: 1UNKNOWN: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06923228Lead Sponsor
A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
PHASE2Not yet recruiting
3 participants
Started: Apr 21, 2025 · Completed: Sep 30, 2025
NCT06810050Lead Sponsor
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
PHASE2Recruiting
180 participants
Started: Dec 18, 2024 · Completed: Oct 30, 2025
NCT05487963Lead Sponsor
Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis
PHASE1/PHASE2Completed
40 participants
Started: Nov 9, 2022 · Completed: Jul 30, 2023
NCT05202366Lead Sponsor
An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection
N/AUnknown
15 participants
Started: Feb 8, 2022 · Completed: Sep 15, 2022
NCT04886739Lead Sponsor
CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea
PHASE2Completed
78 participants
Started: May 7, 2021 · Completed: Dec 22, 2021
Locations (1)
Headquarters
San Carlos, CA, United States
Map
Loading map...